Skip to main content

Advertisement

Log in

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Objectives

The aim of this study was to get insight into the central effects of TC-1734 (renamed AZD3480), a selective agonist at the neuronal nicotinic receptor of the α4β2 subtype.

Materials and methods

Electroencephalography (EEG) techniques and computerized cognitive tests were performed in young, healthy male volunteers during two double-blind and placebo-controlled studies: a rising single dose crossover study (from 2 to 320 mg) and a rising repeated dose study with a parallel group design (50, 100, and 200 mg).

Results

In contrast to acute administration, administration of AZD3480 over 10 days produced statistically significant enhancement of several cognitive measures (attention and episodic memory) compared to placebo. Regarding EEG data, AZD3480 showed acceleration of the alpha centroid and of the alpha peak in the single-dose study. This EEG profile of the acceleration type was confirmed in the repeated dose study on both day 1 and day 10, with the greatest effect observed with the highest dose. The EEG pattern shown for AZD3480 was consistent with that previously described with other drugs known to improve attention and vigilance (including nicotine). In addition, subjects dosed with AZD3480 showed a statistically significant increase in mismatch negativity (MMN) amplitude at 50 and 200 mg while reducing MMN latency (200 mg only), suggesting an improvement of pre-attentional mechanisms.

Conclusion

These early data in healthy subjects provide encouragement to consider development of AZD3480 as a novel agent for the treatment of cognitive decline in the elderly, including age-associated memory impairment and/or dementia of the Alzheimer’s type.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Arthur D, Levin ED (2002) Chronic inhibition of α4β2 nicotinic receptors in the ventral hippocampus of rats: impacts on memory and nicotine response. Psychopharmacology 160:140–145

    Article  PubMed  CAS  Google Scholar 

  • Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209–245

    Article  PubMed  CAS  Google Scholar 

  • Besthorn C, Zerfass R, Geiger-Kabisch C, Sattel H, Daniel S, Schreiter-Gasser U, Forstl H (1997) Discrimination of Alzheimer’s disease and normal aging by EEG data. Electroencephalogr Clin Neurophysiol 103(2):241–248

    Article  PubMed  CAS  Google Scholar 

  • Brassen S, Adler G (2003) Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. Pharmacopsychiatry 36(6):304–308

    Article  PubMed  CAS  Google Scholar 

  • Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM (2005) Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 26:352–360

    Article  PubMed  CAS  Google Scholar 

  • Dago KT, Luthringer R, Lengelle R, Rinaudo G, Macher JP (1994) Statistical decision tree: a tool for studying pharmaco-EEG effects of CNS active drugs. Neuropsychobiology 29:91–96

    Article  PubMed  CAS  Google Scholar 

  • Dierks T, Frölich L, Ihl R, Maurer K (1994) Event-related potentials and psychopharmacology: cholinergic modulation of P300. Pharmacopsychiatry 27:72–74

    PubMed  CAS  Google Scholar 

  • Dunbar G, Kuchibhatla R (2006) Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. J Mol Neurosci 30:169–172

    Article  PubMed  CAS  Google Scholar 

  • Dunbar G, Demazieres A, Monreal A, Cisterni C, Kuchibhatla R, Luthringer R (2006a) Pharmacokinetics and safety profile of ispronicline (TC-1734) a new neuronal nicotinic receptor partial agonist, in healthy young male volunters. J Clin Pharmacol 46(7):715–726

    Article  PubMed  CAS  Google Scholar 

  • Dunbar G, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley JR (2006b) Effect of ispronicline (TC-1734) a neuronal nicotinic receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol (in press, August 4)

  • Edwards J, Wesnes K, Warburton DM, Gale A (1985) Evidence of more rapid stimulus evaluation following cigarette smoking. Addict Behav 10:113–126

    Article  PubMed  CAS  Google Scholar 

  • Engeland C, Mahoney C, Mohr E, Ilivitsky V, Knott VJ (2002) Acute nicotine effects on auditory sensory memory in tacrine treated and nontreated patients with Alzheimer’s disease: an event-related potential study. Pharmacol Biochem Behav 72(1–2):457–464

    Article  PubMed  CAS  Google Scholar 

  • Forstl H, Sattel H, Besthorn C, Daniel S, Geiger-Kabisch C, Hentschel F, Sarochan M, Zerfass R (1996) Longitudinal cognitive, electroencephalographic and morphological brain changes in ageing and Alzheimer’s disease. Br J Psychiatry 168(3):280–286

    Article  PubMed  CAS  Google Scholar 

  • Foulds J, McSorley K, Sneddon J, Feyerabend C, Jarvis MJ, Russel MA (1994) Effect of subcutaneous nicotine injections on EEG alpha frequency in non-smokers: a placebo-controlled pilot study. Psychopharmacology 115(1–2):163–166

    Article  PubMed  CAS  Google Scholar 

  • Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363–936

    Article  PubMed  CAS  Google Scholar 

  • Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10(2):147–166

    Article  PubMed  CAS  Google Scholar 

  • Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 147:1–46

    Article  PubMed  CAS  Google Scholar 

  • Houlihan ME, Pritchard WS, Robinson JH (1996) Faster P300 latency after smoking in visual but not auditory oddball tasks. Psychopharmacology 123:231–238

    Article  PubMed  CAS  Google Scholar 

  • Jelic V, Dierks T, Amberla K, Almkvist O, Winblad B, Nordberg A (1998) Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer’s disease. Neurosci Lett 254:85–88

    Article  PubMed  CAS  Google Scholar 

  • Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy male volunteers. Neuropsychopharmacology 28:542–551

    Article  PubMed  CAS  Google Scholar 

  • Knott V, Bosman M, Mahoney C, Ilivitsky V, Quirt K (1999) Transdermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials. Pharmacol Biochem Behav 63(2):253–261

    Article  PubMed  CAS  Google Scholar 

  • Knott V, Engeland C, Mohr E, Mahoney C, Llivitsky V (2000) Acute nicotine administration in Alzheimer’s disease: an exploratory EEG study. Neuropsychobiology 41:210–220

    Article  PubMed  CAS  Google Scholar 

  • Kowalski JW, Gawel M, Pfeffer A, Barcikowska M (2001) The diagnosis value of EEG in Alzheimer disease. J Clin Neurophysiol 18(6):570–575

    Article  PubMed  CAS  Google Scholar 

  • Lindgren M, Molander L, Verbaan C, Lunell E, Rosén I (1999) Electroencephalograhic effects of intravenous nicotine—a dose-response study. Psychopharmacology 145:335–342

    Article  Google Scholar 

  • Matejcek M (1980) Cortical correlates of vigilance regulation and their use in evaluating the effects of treatment. Adv Biochem Psychopharmacol 23:339–348

    PubMed  CAS  Google Scholar 

  • Meador KJ, Loring DW, Davis HC, Sethi KD, Patel BR, Adams RJ et al (1989) Cholinergic and serotonergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol 11(Suppl 2):252–260

    Article  PubMed  CAS  Google Scholar 

  • Moore TL, Killiany RJ, Herndon JG, Rosene DL, Moss MB (2006) Executive system dysfunction occurs as early as middle-age in the rhesus monkey. Neurobiol Aging 27(10):1484–1493

    Article  PubMed  Google Scholar 

  • Moretti DV, Babiloni C, Binetti G, Cassetta E, Dal Forno G, Ferreric F, Ferri R, Lanuzza B, Miniussi C, Nobili F, Rodriguez G, Salinari S, Rossini PM (2004) Individual analysis of EEG frequency and band power in mild Alzheimer’s disease. Clin Neurophysiol 115:299–308

    Article  PubMed  Google Scholar 

  • Münte TF, Heinze HJ, Scholz M, Künkel H (1988) Effects of a cholinergic nootropic (WEB 1881 FU) on event-related potentials recorded in incidental and intentional memory tasks. Neuropsychobiology 19:158–168

    Article  PubMed  Google Scholar 

  • Münte TF, Heinze HJ, Scholz MB, Bartusch SM, Dietrich DE (1989) Event-related potentials and visual spatial attention: influence of a cholinergic drug. Neuropsychobiology 21:94–99

    Article  PubMed  Google Scholar 

  • Näätänen R, Paavilainen P, Alho K, Reinikainen K, Sams M (1989) Do event-related potentials reveal the mechanism of the auditory sensory memory in the human brain? Neurosci Lett 98:217–221

    Article  PubMed  Google Scholar 

  • Newhouse PA, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer’s disease. Biol Psychiatry 49:268–278

    Article  PubMed  CAS  Google Scholar 

  • Nordberg A (2001) Nicotinic receptor in Alzheimer’s disease: therapeutic implications. Biol Psychiatry 49:200–210

    Article  PubMed  CAS  Google Scholar 

  • Obinu MC, Reibaud M, Miquet JM, Pasquet M, Rooney T (2002) Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog Neuropsychopharmacol Biol Psychiatry 26:913–918

    Article  PubMed  CAS  Google Scholar 

  • Pekkonen E, Jaaskelainen IP, Hietanen M, Huotilainen M, Kaakkola S, Näätänen R, Ilmoniemi RJ, Erkinjuntti T (2000) Mismatch negativity in aging and in Alzheimer’s and Parkinson’s diseases. Audiol Neurootol 5:216–224

    Article  PubMed  CAS  Google Scholar 

  • Pekkonen E, Hirvonen J, Jaaskelainen IP, Kaakkola S, Huttunen J (2001) Auditory sensory memory and the cholinergic system: implications for Alzheimer’s disease. Neuroimage 14(2):376–382

    Article  PubMed  CAS  Google Scholar 

  • Perry EK, Martin-Ruiz CM, Court JA (2001) Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 24:63–68

    Article  PubMed  CAS  Google Scholar 

  • Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (1999) Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzhiemer’s disease. Psychopharmacology 142:334–342

    Article  PubMed  CAS  Google Scholar 

  • Prichep LS, John ER, Ferris SH, Reisberg B, Almas M, Alper K, Cancro R (1994) Quantitative EEG correlates of cognitive deterioration in the elderly. Neurobiol Aging 15(1):85–90

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez G, Vitali P, De Leo C, De Carli F, Girtler N, Nobili F (2002) Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy. Neuropsychobiology 46(1):49–56

    Article  PubMed  CAS  Google Scholar 

  • Saletu B (1996) Pharmacodynamics and EEG. In: Krijzer F, Hermann WM (eds) Advances in pharmaco-EEG. Practical and theoretical considerations in preclinical and clinical studies. Berlin Zentrale Universitätsdruckerer, pp 187–204

  • Saletu B, Anderer P, Saletu-Zylharz GM, Arnold O, Pascual-Marqui RD (2002) Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). Methods Find Exp Clin Pharmacol 24(suppl C):97–120

    CAS  Google Scholar 

  • Wesnes KA, Simpson PM, Thompson S (1994) Cognition enhancement with physostigmine in young volunteers. J Psychopharmacol 8(suppl):A19

    Google Scholar 

  • Wesnes KA, Ward T, McGinty A, Petrini O (2000) The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 152:353–361

    Article  PubMed  CAS  Google Scholar 

  • Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP (1999) Increased neurodegeneration during aging in mice lacking high-affinity nicotine receptors. EMBO J 18(5):1235–1244

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was funded by Targacept Inc., the manufacturer of TC-1734.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Demazières.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dunbar, G., Boeijinga, P.H., Demazières, A. et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 191, 919–929 (2007). https://doi.org/10.1007/s00213-006-0675-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-006-0675-x

Keywords

Navigation